Malin Past Earnings Performance
Past criteria checks 0/6
Malin has been growing earnings at an average annual rate of 24.2%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been declining at an average rate of 69.3% per year.
Key information
24.2%
Earnings growth rate
32.8%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -69.3% |
| Return on equity | 0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Malin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 0 | 4 | 0 |
| 30 Sep 23 | 0 | 6 | 5 | 0 |
| 30 Jun 23 | 0 | 13 | 6 | 0 |
| 31 Mar 23 | 0 | 13 | 5 | 0 |
| 31 Dec 22 | 0 | 13 | 3 | 0 |
| 30 Jun 22 | 0 | 4 | -1 | 0 |
| 31 Mar 22 | 0 | 3 | 1 | 0 |
| 31 Dec 21 | 0 | 3 | 2 | 0 |
| 30 Jun 21 | 0 | 92 | 6 | 0 |
| 31 Mar 21 | 0 | 90 | 6 | 0 |
| 31 Dec 20 | 0 | 89 | 6 | 0 |
| 30 Sep 20 | 17 | 37 | 11 | 2 |
| 30 Jun 20 | 16 | -12 | 12 | 1 |
| 31 Mar 20 | 25 | -9 | 16 | 2 |
| 31 Dec 19 | 35 | -5 | 19 | 3 |
| 30 Sep 19 | 35 | -13 | 19 | 3 |
| 30 Jun 19 | 35 | -20 | 19 | 2 |
| 31 Mar 19 | 36 | -33 | 21 | 3 |
| 31 Dec 18 | 38 | -46 | 24 | 3 |
| 30 Sep 18 | 40 | -70 | 29 | 6 |
| 30 Jun 18 | 43 | -94 | 35 | 8 |
| 31 Mar 18 | 42 | -97 | 40 | 10 |
| 31 Dec 17 | 42 | -99 | 45 | 12 |
| 30 Sep 17 | 42 | -87 | 49 | 9 |
| 30 Jun 17 | 41 | -74 | 53 | 7 |
| 31 Mar 17 | 42 | -79 | 53 | 6 |
| 31 Dec 16 | 42 | -83 | 53 | 5 |
| 30 Jun 16 | 41 | -52 | 27 | 5 |
| 31 Dec 15 | 21 | -41 | 26 | 2 |
Quality Earnings: MLLN.F is currently unprofitable.
Growing Profit Margin: MLLN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLLN.F is unprofitable, but has reduced losses over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare MLLN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLLN.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: MLLN.F has a negative Return on Equity (0%), as it is currently unprofitable.